Serbia receives million doses of China's Sinopharm COVID-19 vaccine

3 minute read
Register now for FREE unlimited access to

BELGRADE, Jan 16 (Reuters) - A plane carrying one million doses of Sinopharm's (1099.HK) COVID-19 vaccine arrived on Saturday in Serbia, making it the first European country to receive the Chinese vaccine for mass inoculation programmes.

President Aleksandar Vucic was accompanied by Beijing's ambassador to the Balkan country at Belgrade's airport as containers carrying the vaccines were unloaded from an Air Serbia plane.

"I would like to thank President Xi Jinping and Chinese leadership for sending us one million doses of the vaccine," Vucic, who has helped forge close ties with China in recent years, told reporters.

Register now for FREE unlimited access to

He said Serbia's medical regulator was expected to approve the Sinopharm vaccine in the next few days, allowing vaccinations with the doses to start within a week.

More than 20,000 Serbians have so far been vaccinated since the mass inoculation began in late December, mainly elderly people in retirement homes and medical workers.

Most have received the vaccine developed by Pfizer (PFE.N) and BioNTech (22UAy.DE) or Russia's Sputnik vaccine.

Vucic said Serbia expects to get another 250,000 doses of the Sputnik vaccine and 20,000 doses of Pfizer vaccines next week. He also said the Balkan country expects to get shipments of AstraZeneca (AZN.L) and Moderna (MRNA.O) vaccines by June.

Neighbouring Hungary expects its medical regulator to approve use of the Sinopharm vaccine for mass inoculation, after the European Commision gave its clearance for it to negotiate Sinopharm vaccine supply. read more

In the Western Balkan region, inoculation has started only in Serbia and Albania. Bosnia, Kosovo, Montenegro and North Macedonia have not yet received supplies of any vaccine.

China approved the shot developed by Sinopharm's BIBP in late December, its first COVID-19 vaccine for general public use. No detailed efficacy data has been released but BIBP has said the vaccine is 79.34% effective based on interim data.

Register now for FREE unlimited access to
Reporting by Ivana Sekularac Editing by Helen Popper

Our Standards: The Thomson Reuters Trust Principles.